CERO CERO THERAPEUTICS HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1870404 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-259.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,130.6%
Debt / equity—
Current ratio0.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.61x
Accruals ratio157.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | — | $5.29M | — |
| SG&A expense | — | $2.39M | $2.84M |
| Operating income | — | -$7.68M | -$2.91M |
| Interest expense | — | -$138,340 | — |
| Pretax income | -$19.92M | -$2.44M | -$68,577 |
| Income tax | — | $94,819 | $599,159 |
| Net income | -$19.92M | -$7.29M | -$667,736 |
| EPS (basic) | — | -1,248.64 | — |
| EPS (diluted) | — | -1,248.64 | — |
| Dividends declared per share | 10.37 | — | — |
| Weighted avg. shares (diluted) | — | 5,838 | — |
| Banking | |||
| Deposits | $1.30M | — | — |
| Balance sheet | |||
| Cash & equivalents | $1.66M | $1.60M | $475,870 |
| Current assets | $2.73M | $1.97M | $42.37M |
| PP&E, net | $246,148 | $966,702 | — |
| Total assets | $3.64M | $5.13M | $42.37M |
| Current liabilities | $9.09M | $3.51M | $30.75M |
| Total liabilities | $9.09M | $5.08M | $39.90M |
| Shareholders' equity | -$5.45M | -$42.06M | -$11.00M |
| Shares outstanding | — | 5,845 | — |
| Cash flow statement | |||
| Operating cash flow | -$16.10M | -$1.52M | -$1.09M |
| Investing cash flow | — | -$7.94M | $180.84M |
| Financing cash flow | — | -$32.58M | -$138.70M |
| Stock-based compensation | $1.10M | $96,896 | — |
| Dividends paid | $127,144 | — | — |
| Share buybacks | — | $33.48M | $139.35M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.